What is Non-Small Cell Lung Cancer (NSCLC)?
Non-small cell lung cancer (NSCLC) is the most common lung cancer type that accounts for around 85% of all lung cancer diagnoses. It tends to grow more slowly than small-cell lung cancer, but it often produces no symptoms in the early stages, meaning it is frequently diagnosed only after it has already spread. Early detection and the right treatment plan make a significant difference in outcomes.
Types of Non-Small Cell Lung Cancer
NSCLC is grouped into three main subtypes, each with different behaviour and treatment responses.
Adenocarcinoma
Adenocarcinoma makes up about 40% of all NSCLC cases. It begins in the mucus-producing cells in the outer parts of the lungs. This is the subtype most commonly seen in non-smokers and links closely to targetable genetic mutations like EGFR, ALK, and ROS1. Compared to other subtypes, it usually grows at a slower pace.
Squamous Cell Carcinoma
Squamous cell carcinoma (SCC) accounts for 25 to 30% of NSCLC cases. It develops in the flat cells lining the bronchi, typically in the central lung. This subtype is more closely linked to smoking than any other type of NSCLC.
Large-Cell Carcinoma
Large-cell carcinoma makes up 10 to 15% of NSCLC diagnoses. It can occur anywhere in the lung. It tends to grow and spread aggressively compared to other subtypes.
Symptoms of Non-Small Cell Lung Cancer
One of the biggest challenges with NSCLC is that it often produces no noticeable signs early on. According to research, around 40% of cases have already spread beyond the lungs by the time of diagnosis.
Common symptoms include:
- A persistent cough that does not go away
- Shortness of breath or wheezing
- Chest pain that worsens while deep breathing or coughing
- Coughing up blood or bloody mucus
- Hoarseness or a change in voice quality
- Unexplained fatigue or loss of appetite
- Unintentional weight loss
When cancer has spread to other parts of the body, additional symptoms may appear, including bone pain, headaches, and swelling in the face and neck. Because these symptoms overlap with many common conditions, lung cancer is often not suspected until it has already advanced.
Stages of NSCLC
The NCI stages NSCLC from Stage I (localised) through Stage IV (widely spread). The stage at the time of diagnosis is one of the most crucial factors in determining which treatments are appropriate and what outcomes are likely.
Treatment Options for Non-Small Cell Lung Cancer
Surgery
Surgery is the main treatment for early-stage NSCLC (Stages I and II) where the tumour has not spread to distant sites. Common surgical approaches include lobectomy (removal of a lobe of the lung), segmentectomy, and pneumonectomy (removal of the entire lung).
Radiation Therapy
High-energy beams are utilized in radiation therapy to kill cancer cells. It is used when surgery is not possible, to shrink a tumour before surgery, or to treat any remaining cancer cells afterwards. Stereotactic body radiation therapy (SBRT) is a precise, high-dose form used for early-stage NSCLC in patients who cannot have surgery.
Chemotherapy
Chemotherapy works by killing cancer cells or slowing how fast they grow. Oncologists use it together with radiation for locally advanced disease, before surgery to shrink the tumor, or after surgery to reduce the risk of the cancer coming back.
Targeted Therapy
Targeted therapy is one of the biggest advances in treating NSCLC. A few subtypes, like adenocarcinoma, often have genetic mutations that drive cancer growth. Drugs that block these mutations, such as EGFR or ALK inhibitors, can be highly effective while sparing healthy tissue. Biomarker testing should be completed before starting targeted therapy to confirm whether a treatable mutation is present.
Immunotherapy
Immunotherapeutic agents work by helping the immune system find and attack cancer cells. They have transformed outcomes for many NSCLC patients, particularly in later stages, and are used alone or combined with chemotherapy.
The Role of Biomarker Testing
Biomarker testing analyses tumour tissue to identify specific genetic mutations or proteins present in the cancer. According to research, this is a critical step that allows oncologists to match patients with the most effective targeted or immunotherapy treatments. For adenocarcinoma patients, testing for EGFR, ALK, ROS1, KRAS, and PD-L1 is now standard practice before treatment begins.
Conclusion
NSCLC is the most common lung cancer form. Its course can vary widely depending on when it is detected and how it responds to treatment. Symptoms of NSCLC should never be ignored, especially in individuals with known risk factors like smoking or long-term exposure to pollutants. Early medical evaluation helps identify disease when more treatment options are available. Advances in surgical techniques, targeted therapy, and immunotherapy have expanded patient choices, while radiation treatment remains essential.
Many patients can benefit from customized treatment plans based on the specific characteristics of their tumor. With early diagnosis, appropriate therapy, and continuous medical support, it is possible to manage lung cancer more effectively and improve both survival and quality of life (QoL). If you are experiencing persistent respiratory symptoms or have to discuss your risk for lung cancer, you can connect with a pulmonologist online.
